Matthew A. Spear net worth and biography

Matthew Spear Biography and Net Worth

Insider of Poseida Therapeutics

Dr. Spear joined Poseida as Chief Medical Officer in June of 2016. From April 2016 until July 2016, Dr. Spear served as head of Clinical Development and Vice President at Sangamo Biosciences Inc. From 2014 to 2016, Dr. Spear was Vice President, Clinical Development and Translational Medicine at Incyte Corporation, a research company specializing in oncology product development and innovative medicines. Dr. Spear served as head of oncology and head of biotherapeutics at Sunovion Pharmaceuticals, Inc. from January 2012 to July 2014. From 2005 to 2011, Dr. Spear held several roles at Nereus Pharmaceuticals, Inc., most recently he served as Chief Medical Officer. Prior to joining Nereus, Dr. Spear led multiple oncology clinical development programs at Pfizer as an associate professor at the Keck School of Medicine of USC, and the UCSD School of Medicine and UCSD Cancer Center. He has also served on NIH/NCI study section, biotechnology and pharmaceutical advisory boards, IRB/SRC and scientific journal editorial review committees related to cancer, as well as authoring numerous scientific papers and patents. His residency and fellowship was conducted in the Massachusetts General Hospital/Harvard University program. Dr. Spear received his M.D. from Stanford University Medical School and his B.S. and B.A. in biology from Johns Hopkins University.

What is Matthew A. Spear's net worth?: The estimated net worth of Matthew A. Spear is at least $430,288.10 as of August 20th, 2021. Dr. Spear owns 45,485 shares of Poseida Therapeutics stock worth more than $430,288 as of December 27th. This net worth estimate does not reflect any other assets that Dr. Spear may own. Learn More about Matthew A. Spear's net worth.
How do I contact Matthew A. Spear?: The corporate mailing address for Dr. Spear and other Poseida Therapeutics executives is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. Poseida Therapeutics can also be reached via phone at 858-779-3100 and via email at [email protected]. Learn More on Matthew A. Spear's contact information.
Has Matthew A. Spear been buying or selling shares of Poseida Therapeutics?: Matthew A. Spear has not been actively trading shares of Poseida Therapeutics during the last ninety days. Most recently, Matthew A. Spear sold 4,000 shares of the business's stock in a transaction on Friday, August 20th. The shares were sold at an average price of $8.79, for a transaction totalling $35,160.00. Following the completion of the sale, the insider now directly owns 45,485 shares of the company's stock, valued at $399,813.15. Learn More on Matthew A. Spear's trading history.
Who are Poseida Therapeutics' active insiders?: Poseida Therapeutics' insider roster includes Kerry Ingalls (COO), Eric Ostertag (CEO), and Matthew Spear (Insider). Learn More on Poseida Therapeutics' active insiders.
Are insiders buying or selling shares of Poseida Therapeutics?: During the last twelve months, insiders at the sold shares 2 times. They sold a total of 60,000 shares worth more than $561,900.00. The most recent insider tranaction occured on December, 10th when Chairman Mark J Gergen sold 30,000 shares worth more than $283,800.00. Insiders at Poseida Therapeutics own 2.9% of the company. Learn More about insider trades at Poseida Therapeutics.
Information on this page was last updated on 12/10/2024.

Matthew A. Spear Insider Trading History at Poseida Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/20/2021	Sell	4,000	$8.79	$35,160.00	45,485
6/11/2021	Sell	4,000	$9.44	$37,760.00	20,485
4/21/2021	Sell	4,000	$8.44	$33,760.00	15,485

Matthew A. Spear Buying and Selling Activity at Poseida Therapeutics

Poseida Therapeutics Company Overview

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Today's Range

Now: $9.46

$9.45

$9.48

50 Day Range

MA: $5.82

$2.37

$9.51

2 Week Range

Now: $9.46

$1.87

$9.58

Volume

59,473 shs

Average Volume

733,782 shs

Market Capitalization

$924.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol